Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating expenses:        
Research and development $ (1,845) $ (3,937) $ (7,010) $ (18,723)
General and administrative (3,029) (2,398) (10,698) (8,759)
Total operating expenses (4,874) (6,335) (17,708) (27,482)
Operating loss (4,874) (6,335) (17,708) (27,482)
Interest expense, net (849) (4,183) (4,781) (10,854)
Financing transaction costs   (685)   (2,815)
Adjustments to fair value of derivatives 9,783 (644) (64,526) 1,023
Other income, net 33 68 167 27
Total other income / (expense), net 8,967 (5,444) (69,140) (12,619)
Income / (loss) before income taxes 4,093 (11,779) (86,848) (40,101)
Income tax expense (352) (420) (534) (719)
Net income / (loss) and comprehensive income / (loss) 3,741 (12,199) (87,382) (40,820)
Net income / (loss) attributable to ordinary shareholders $ 3,741 $ (12,199) $ (87,382) $ (40,820)
Net income / (loss) per share attributable to ordinary shareholders – basic $ 0.02 $ (0.60) $ (0.56) $ (2.39)
Net income / (loss) per share attributable to ordinary shareholders – diluted $ 0.02 $ (0.60) $ (0.56) $ (2.39)
Weighted average ordinary shares outstanding – basic 182,730,032 20,392,357 156,058,343 17,078,326
Weighted average ordinary shares outstanding – diluted 202,257,112 20,392,357 156,058,343 17,078,326